Literature DB >> 6315113

Normal titer of functional and immunoreactive protein-C inhibitor in plasma of patients with congenital combined deficiency of factor V and factor VIII.

K Suzuki, J Nishioka, S Hashimoto, T Kamiya, H Saito.   

Abstract

Protein-C inhibitor (PCI) is a newly described plasma inhibitor directed against a vitamin-K-dependent serine protease, activated protein-C, which is involved in the inactivation of factor V and factor VIII. Marlar and Griffin have reported that PCI activity is absent in the plasma of patients with congenital combined factor V/VIII deficiency. We have measured the levels of PCI in the plasma of seven unrelated patients with this disorder using both functional and immunologic methods. The rate at which the amidolytic activity of activated protein-C was neutralized in the patients' plasma was essentially identical to that observed in normal plasma. The titer of PCI antigen, as measured by an electroimmunoassay using a monospecific anti-PCI serum, was 5.3 +/- 1.6 micrograms/ml in the patients' plasma and was not significantly different from that of normal plasma (5.3 +/- 2.7 micrograms/ml, n = 30). The levels of factor-V-related antigen, factor V coagulant antigen, and factor VIII coagulant antigen were low in all patient plasma and were in good agreement with their respective coagulant activity. Our results do not appear to support the hypothesis that combined factor V/VIII defect is due to a lack of PCI.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6315113

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

1.  Linkage of combined factors V and VIII deficiency to chromosome 18q by homozygosity mapping.

Authors:  W C Nichols; U Seligsohn; A Zivelin; V H Terry; N D Arnold; D R Siemieniak; R J Kaufman; D Ginsburg
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

2.  The locus for combined factor V-factor VIII deficiency (F5F8D) maps to 18q21, between D18S849 and D18S1103.

Authors:  M Neerman-Arbez; S E Antonarakis; J L Blouin; S Zeinali; M Akhtari; Y Afshar; E G Tuddenham
Journal:  Am J Hum Genet       Date:  1997-07       Impact factor: 11.025

Review 3.  The COPII pathway and hematologic disease.

Authors:  Rami Khoriaty; Matthew P Vasievich; David Ginsburg
Journal:  Blood       Date:  2012-05-14       Impact factor: 22.113

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.